报价延迟最少15分钟:2025/09/15 09:03 EDT
盘前时段
|
||||
|
17.8 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.65/0.15
|
|
企业价值
3.14B
|
| 资产负债 |
|
每股账面净值
7.15
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
227.98M
|
|
每股收益
4.41
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/15 09:03 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
